Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C
Resources
Showing 51 to 60 of 310 resources
-
Good practice case study: Oxford Liaison Service outreach
This HCV Action good practice case study looks at the community outreach work done by Oxford University Hospitals NHS Foundation Trust. A survey of injecting drug users in the Oxfordshire area to determine levels of hepatitis C testing found that a third of responders had never been tested for hepatitis C. Following the survey results, the Trust established a Liaison Service, training substance misuse staff to test clients for hepatitis C, referring patients to secondary care and, in some cases, treating patients in the community.UK, South East Case study PDF -
Road to Elimination: Barriers and Best Practices in Hepatitis C Management
This report provides an overview of the status of HCV care in Europe and Australia. Through literature review and country experts’ consultation conducted between November 2016 and March 2017, the report analyses the status of 11 countries, identifying and comparing key success factors and main barriers for each step of the HCV care cascade: (1) awareness and prevention; (2) testing and diagnosis; (3) linkage to care and access to qualified health services; (4) access to medication; and (5) monitoring and evaluation.UK, Rest of World Reports & Research, Strategy & Planning PDF -
Unlinked anonymous HIV and viral hepatitis monitoring among PWID: 2017 report
This report presents an overview of the trends between 2006 and 2016 for HIV, hepatitis B, hepatitis C and risk behaviours from the ongoing Unlinked Anonymous Monitoring Survey, which is targeted at people who inject psychoactive drugs, such as heroin, crack cocaine and amphetamines.UK Reports & Research PDF -
Hepatitis C in the UK 2017 report
The ninth Hepatitis C in the UK report follows the WHO Global Health Sector Strategy (GHSS) on Viral Hepatitis 2016-2021 and the draft action plan for the health sector response to viral hepatitis in the WHO European region. The report is structured to support UK monitoring of the GHSS goals and summarises the impact of UK action plans to drive down mortality from HCV and reduce the number of new infections.UK Reports & Research, Strategy & Planning PDF -
Financial case for action on liver disease
This report, produced by the Foundation for Liver Research and endorsed by the Lancet Commission on Liver Disease, examines the financial costs of viral hepatitis, along with alcohol misuse and obesity. The report also carries recommendations, which include improving access to testing for hepatitis C and protecting harm reduction services such as needle exchange and opioid substitution for injecting drug users.UK Reports & Research PDF -
Summary report: North East & Cumbria ODN Workshop, Newcastle
This report provides a summary of the North East & Cumbria ODN Workshop held by HCV Action, in partnership with the ODN, in Newcastle on Wednesday 3rd May 2017. The workshop brought together a range of stakeholders working across the hepatitis C pathway in the North East & Cumbria ODN region, with the aim of discussing some of the barriers faced by the ODN, as well as providing a forum in which to develop solutions to some of these challenges. The report includes summaries of the day's talks and group discussion, as well as suggested next steps to be taken following the event.North East, UK Reports & Research PDF -
Template Operational Delivery Network Memorandum of Understanding
Developed with the Eastern Hepatitis Network, this template Memorandum of Understanding (MOU) is a resource that can be used by Operational Delivery Networks to agree the responsibilities, obligations and rights of each party when collaborating with other services.England Tools & Templates MS Word -
Reduction in Liver Transplant Wait-Listing in the Era of Direct-Acting Antiviral Therapy
This paper analyses trends in liver transplant wait-listing to explore the potential impact of direct acting antiviral (DAA) treatments for hepatitis C on wait-listing registration. The authors conclude that the rate of liver transplant wait-listing for hepatitis C complicated by decompensated cirrhosis has decreased by over 30% in the era of DAA therapy. Further reductions in wait-listing are anticipated with increased testing, linkage to care, and access to DAA therapy.Rest of World Reports & Research PDF -
Good practice case study: Ipswich NHS Trust prison in-reach
In August 2015, Ipswich NHS Trust launched an in-reach treatment service in four prisons, seeking to increase the number of inmates receiving treatment for hepatitis C. Despite a number of challenges, clear pathways have been established for engaging patients into treatment, which has resulted in a substantial increase in the number of prisoners being treated for the virus.UK, England, East of England Case study PDF -
Hepatitis B and C testing activities, needs, and priorities in the EU/EEA
Hepatitis B and C virus infections are associated with a considerable burden of disease in Europe. The European Centre for Disease Prevention and Control undertook a survey to assess needs and priorities prior to developing guidance on testing and screening for hepatitis B and C in the EU/EEA, and to update the existing evidence on the burden of HBV/HCV morbidity and mortality across EU/EEA Member States.Rest of World Reports & Research PDF